Destiny Pharma PLC

LSE:DEST (UK)  
£ 0.16 (0%) Jun 7
At Loss
P/B:
1.64
Market Cap:
£ 15.04M ($ 19.11M)
Enterprise V:
£ 8.66M ($ 11.00M)
Volume:
322.15K
Avg Vol (2M):
534.71K
Also Trade In:
Volume:
322.15K
At Loss
Avg Vol (2M):
534.71K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Destiny Pharma PLC ( ) from 2017 to Jun 09 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Destiny Pharma PLC stock (LSE:DEST) PE ratio as of Jun 09 2024 is 0. More Details

Destiny Pharma PLC (LSE:DEST) PE Ratio (TTM) Chart

To

Destiny Pharma PLC (LSE:DEST) PE Ratio (TTM) Historical Data

Total 1279
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 15
Destiny Pharma PLC PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-09 At Loss 2024-04-04 At Loss
2024-06-07 At Loss 2024-04-03 At Loss
2024-06-06 At Loss 2024-04-02 At Loss
2024-06-05 At Loss 2024-03-28 At Loss
2024-06-04 At Loss 2024-03-27 At Loss
2024-06-03 At Loss 2024-03-26 At Loss
2024-05-31 At Loss 2024-03-25 At Loss
2024-05-30 At Loss 2024-03-22 At Loss
2024-05-29 At Loss 2024-03-21 At Loss
2024-05-28 At Loss 2024-03-20 At Loss
2024-05-24 At Loss 2024-03-19 At Loss
2024-05-23 At Loss 2024-03-18 At Loss
2024-05-22 At Loss 2024-03-15 At Loss
2024-05-21 At Loss 2024-03-14 At Loss
2024-05-20 At Loss 2024-03-13 At Loss
2024-05-17 At Loss 2024-03-12 At Loss
2024-05-16 At Loss 2024-03-11 At Loss
2024-05-15 At Loss 2024-03-08 At Loss
2024-05-14 At Loss 2024-03-07 At Loss
2024-05-13 At Loss 2024-03-06 At Loss
2024-05-10 At Loss 2024-03-05 At Loss
2024-05-09 At Loss 2024-03-04 At Loss
2024-05-08 At Loss 2024-03-01 At Loss
2024-05-07 At Loss 2024-02-29 At Loss
2024-05-03 At Loss 2024-02-28 At Loss
2024-05-02 At Loss 2024-02-27 At Loss
2024-05-01 At Loss 2024-02-26 At Loss
2024-04-30 At Loss 2024-02-23 At Loss
2024-04-29 At Loss 2024-02-22 At Loss
2024-04-26 At Loss 2024-02-21 At Loss
2024-04-25 At Loss 2024-02-20 At Loss
2024-04-24 At Loss 2024-02-19 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-12 At Loss
2024-04-16 At Loss 2024-02-09 At Loss
2024-04-15 At Loss 2024-02-08 At Loss
2024-04-12 At Loss 2024-02-07 At Loss
2024-04-11 At Loss 2024-02-06 At Loss
2024-04-10 At Loss 2024-02-05 At Loss
2024-04-09 At Loss 2024-02-02 At Loss
2024-04-08 At Loss 2024-02-01 At Loss
2024-04-05 At Loss 2024-01-31 At Loss

Destiny Pharma PLC (LSE:DEST) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Destiny Pharma PLC is a clinical-stage biotechnology company that is focused on the development of medicines for the treatment of infectious diseases. It is developing drugs for the prevention and treatment of infections caused by Antibiotic-Resistant (AR) bacteria. It is involved in developing XF-73 Dermal for the treatment of skin infections of antibiotic-resistant bacteria, XF-73 Nasal for the prevention of post-surgical staphylococcal infection, and NTCD-M3 among others.